Related Experiment Video

Updated: Aug 7, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Selective killing of cancer cells based on translational control of a suicide gene

Robert J DeFatta1, Yuan Li, Arrigo De Benedetti

  • 1Department of Biochemistry and Molecular Biology and the Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130-3932, USA.

Cancer Gene Therapy
|June 26, 2002
PubMed

Insights

Overexpressed translation factor eIF4E enables cancer cells to produce HTK, selectively killing them with ganciclovir. Modulating eIF4E expression controls cancer cell sensitivity to this drug.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The translation initiation factor eIF4E is frequently overexpressed in solid tumors.
  • Elevated eIF4E levels promote the translation of specific mRNAs encoding growth-promoting proteins.
  • This mechanism allows cancer cells to bypass normal translational repression.

Purpose of the Study:

  • To investigate the selective killing of cancer cells by modulating HTK synthesis at the translational level.
  • To explore the role of eIF4E in cancer cell sensitivity to ganciclovir.

Main Methods:

  • Exploiting the property of eIF4E overexpression to modulate HTK synthesis.
  • Utilizing ganciclovir as a therapeutic agent.
  • Altering eIF4E expression levels in various cell lines.

Main Results:

  • Breast cancer cell lines efficiently synthesized HTK from translationally regulated mRNA, unlike normal cells.
  • Low concentrations of ganciclovir selectively killed cancer cells.
  • Modulating eIF4E expression altered the sensitivity of cell lines to ganciclovir.

Conclusions:

  • Targeting eIF4E-mediated translation offers a strategy for selective cancer cell killing.
  • The expression level of eIF4E is a key determinant of ganciclovir sensitivity in cancer cells.
  • This approach holds potential for developing targeted cancer therapies.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...